1. Immunotherapies: Key Considerations in the Identification and Management of irAEs

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Immunotherapy Is a Broad Field

5. Mode Of Action of Checkpoint Blockade

6. Approved Checkpoint Inhibitors

7. irAEs

8. irAEs of Particular Concern

9. Case 1: 54-Year-Old Woman

10. Diagnosis of Rash as an irAE

11. Management of Immune-Related Rash

12. Case 1 Follow-Up

13. Diagnosis of Hypothyroidism as an irAE

14. Management of Hypothyroidism

15. Case 2: 67-Year-Old Woman

16. Diagnosis of Colitis as an irAE

17. Management of Colitis

18. Case 2 Follow-Up

19. Diagnosis of Hepatitis as an irAE

20. Management of Hepatitis

21. Routine Monitoring Recommendations

22. General irAE Management Strategies

23. Cardiotoxicity as an irAE

24. Clinical Pearls

25. Abbreviations

26. Abbreviations (cont)

27. Abbreviations (cont)